Last reviewed 2026-05-30 · How we verify

Cyclamid (GLYCYCLAMIDE)

Phase 2 active Small molecule ✓ Verified May 2026

Cyclamid (generic name: GLYCYCLAMIDE) is a glycyclamide drug. It is currently in Phase 2 development.

Cyclamid works by inhibiting a specific enzyme or pathway, although the exact details are not publicly available.

Cyclamid is a small molecule with the synonyms GLICICLAMIDA, GLYCYCLAMIDE, K-38, K-386, NSC-142661, and TOLCYCLAMIDE.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	GLYCYCLAMIDE
Drug class	glycyclamide
Modality	Small molecule
Therapeutic area	Metabolic
Phase	Phase 2

Mechanism of action

Imagine your body has a factory that produces a certain chemical. Cyclamid is like a key that locks the factory door, preventing the chemical from being made. This can help treat certain conditions by reducing the amount of the chemical in the body.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cyclamid CI brief — competitive landscape report
Cyclamid updates RSS · CI watch RSS

Frequently asked questions about Cyclamid

What is Cyclamid?

Cyclamid (GLYCYCLAMIDE) is a glycyclamide drug.

How does Cyclamid work?

Cyclamid works by inhibiting a specific enzyme or pathway, although the exact details are not publicly available.

What is the generic name of Cyclamid?

GLYCYCLAMIDE is the generic (nonproprietary) name of Cyclamid.

What drug class is Cyclamid in?

Cyclamid belongs to the glycyclamide class. See all glycyclamide drugs at /class/glycyclamide.

What development phase is Cyclamid in?

Cyclamid is in Phase 2.

Drug class: All glycyclamide drugs
Therapeutic area: All drugs in Metabolic

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing